Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

John David Chetwood Yvonne Tran Sreedhar Subramanian Philip J SmithMarisa IborraAnthony BuissonSudarshan ParamsothyRupert W L Leong

Published in: Journal of Crohn's & colitis (2024)

Changing patients established on IV infliximab to an SC formulation is associated with a high ongoing clinical remission and a low adverse event rate. Furthermore, there are no signals for adverse outcomes among different IBD disease subtypes, nor in those on escalated IV infliximab dosing schedules up to 10 mg/kg 6-weekly. These data should provide patients and clinicians alike with confidence in SC infliximab use in IBD.

Keyphrases

end stage renal disease
ulcerative colitis
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
rheumatoid arthritis
big data
low dose
deep learning
adverse drug
artificial intelligence